Data suggest that the United States had the second highest number of mesothelioma cases and the second highest number of deaths from mesothelioma in 2021. These data were published in Lung Cancer. For ...

Our real-world findings indicate that most patients undergoing multiple lines of therapy experience persistent treatment refractoriness and low response rates,” the researchers wrote.

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.

The Trump administration is attempting to slash NIH funding, terminate research grants, and reduce the agency’s workforce.

Ensuring timely completion of post-approval studies and enforcing appropriate regulatory actions based on negative trial results is necessary to minimize patient exposure to ineffective and ...

The US Senate has confirmed the appointment of Mehmet Oz, MD, to head the Centers for Medicare & Medicaid Services.

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

On April 1, the Trump administration slashed the organization that supported that research — the Agency for Healthcare ...

Artificial intelligence (AI) can accurately suggest appropriate adjuvant treatment for patients with early breast cancer, according to research published in JCO Clinical Cancer Informatics.